{"id":403488,"date":"2020-12-21T07:33:37","date_gmt":"2020-12-21T12:33:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403488"},"modified":"2020-12-21T07:33:37","modified_gmt":"2020-12-21T12:33:37","slug":"provention-bio-announces-addition-to-nasdaq-biotechnology-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/","title":{"rendered":"Provention Bio Announces Addition to NASDAQ Biotechnology Index"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">RED BANK, N.J.<\/span>, <span class=\"xn-chron\">Dec. 21, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open today. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg\" title=\"(PRNewsfoto\/Provention Bio, Inc.)\" alt=\"(PRNewsfoto\/Provention Bio, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market<sup>\u00ae<\/sup> (NASDAQ<sup>\u00ae<\/sup>) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.<\/p>\n<p>The NASDAQ Biotechnology Index forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF (Nasdaq:\u00a0IBB). More information about the Index can be found at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3018650-1&amp;h=2176369237&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3011662-1%26h%3D4170669056%26u%3Dhttps%253A%252F%252Findexes.nasdaqomx.com%252FIndex%252FOverview%252FNBI%26a%3Dhttps%253A%252F%252Findexes.nasdaqomx.com%252FIndex%252FOverview%252FNBI&amp;a=www.nasdaq.com.\" rel=\"nofollow noopener noreferrer\">www.nasdaq.com.<\/a><\/p>\n<p>\n        <b>About Provention Bio, Inc.: <br \/><\/b>Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a Biologics License Alliance\u00a0 (BLA) to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes in at-risk individuals. The Company&#8217;s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and\/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3018650-1&amp;h=353592325&amp;u=http%3A%2F%2Fwww.proventionbio.com%2F&amp;a=www.ProventionBio.com\" rel=\"nofollow noopener noreferrer\">www.ProventionBio.com<\/a>\u00a0for more information and follow us on Twitter: @ProventionBio.<\/p>\n<p>\n        <b>Internet Posting of Information:<br \/><\/b>Provention Bio, Inc. uses its website,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3018650-1&amp;h=2859187213&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2971925-1%26h%3D1416091630%26u%3Dhttp%253A%252F%252Fwww.proventionbio.com%252F%26a%3Dwww.proventionbio.com&amp;a=www.proventionbio.com\" rel=\"nofollow noopener noreferrer\">www.proventionbio.com<\/a>, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company&#8217;s website in the &#8220;News&#8221; section. Accordingly, investors should monitor this portion of the Company&#8217;s website, in addition to following its press releases,\u00a0SEC\u00a0filings and public conference calls and webcasts.<\/p>\n<p>\n        <b>Investor Contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Sam Martin<\/span>, Argot Partners<br \/><u><a target=\"_blank\" href=\"mailto:sam@argotpartners.com\" rel=\"nofollow noopener noreferrer\">sam@argotpartners.com<\/a><\/u>\u00a0 \u00a0<br \/>212-600-1902<\/p>\n<p>\n        <b>Media Contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Lori Rosen<\/span>, LDR Communications<br \/><a target=\"_blank\" href=\"mailto:lori@ldrcommunications.com\" rel=\"nofollow noopener noreferrer\">lori@ldrcommunications.com<\/a><br \/>917-553-6808<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY29783&amp;sd=2020-12-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/provention-bio-announces-addition-to-nasdaq-biotechnology-index-301196521.html\">http:\/\/www.prnewswire.com\/news-releases\/provention-bio-announces-addition-to-nasdaq-biotechnology-index-301196521.html<\/a><\/p>\n<p>SOURCE  Provention Bio, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY29783&amp;Transmission_Id=202012210730PR_NEWS_USPR_____NY29783&amp;DateId=20201221\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire RED BANK, N.J., Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open today. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria. The NASDAQ &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Provention Bio Announces Addition to NASDAQ Biotechnology Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403488","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire RED BANK, N.J., Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open today. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria. The NASDAQ &hellip; Continue reading &quot;Provention Bio Announces Addition to NASDAQ Biotechnology Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T12:33:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Provention Bio Announces Addition to NASDAQ Biotechnology Index\",\"datePublished\":\"2020-12-21T12:33:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/\"},\"wordCount\":373,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/\",\"name\":\"Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"datePublished\":\"2020-12-21T12:33:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Provention Bio Announces Addition to NASDAQ Biotechnology Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/","og_locale":"en_US","og_type":"article","og_title":"Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk","og_description":"PR Newswire RED BANK, N.J., Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open today. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria. The NASDAQ &hellip; Continue reading \"Provention Bio Announces Addition to NASDAQ Biotechnology Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T12:33:37+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Provention Bio Announces Addition to NASDAQ Biotechnology Index","datePublished":"2020-12-21T12:33:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/"},"wordCount":373,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/","name":"Provention Bio Announces Addition to NASDAQ Biotechnology Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","datePublished":"2020-12-21T12:33:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-announces-addition-to-nasdaq-biotechnology-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Provention Bio Announces Addition to NASDAQ Biotechnology Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403488"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403488\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}